Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
To report a suspected adverse event with a Servier drug, please visit servier.com
medication for cardiological & rheumatological conditions & as well as for diabetes & clinical
Outlook, MailChimp SPF, VueJS, SuccessFactors (SAP), React Redux, Mobile Friendly, YouTube, Apache, AddThis, Google Tag Manager, Facebook Custom Audiences, WordPress.org, Bootstrap Framework, Facebook Widget, Facebook Login (Connect)